Psyence BioMed is also pleased to announce that PsyLabs will be participating as a Gold Sponsor at ICPR 2026 – the Interdisciplinary Conference on Psychedelic Research – taking place June 4–6 in Haarlem, The Netherlands.

ICPR is recognized as one of the leading global gatherings for psychedelic science, bringing together researchers, clinicians, regulators, industry leaders, and policymakers to discuss the latest developments in psychedelic medicine and mental health innovation.

Representing the Company and PsyLabs at the conference will be Jody Aufrichtig, CEO of Psyence BioMed; Tony Budden, CEO of PsyLabs; Dr. John Thorne, International Partnerships & Business Development; and Cody Futeran, Extraction Innovations. The team will engage with stakeholders from around the world to discuss advances in psychedelic therapeutics, pharmaceutical-grade manufacturing, natural product sourcing, extraction technologies, and the infrastructure required to support the responsible growth of the sector.

As interest in both psilocybin and ibogaine continues to accelerate globally, conferences such as ICPR provide valuable opportunities to strengthen existing relationships, establish new partnerships, and showcase the capabilities that Psyence BioMed and PsyLabs have developed across manufacturing, research support, and supply chain operations.

The Company looks forward to contributing to the scientific and industry dialogue taking place at ICPR and advancing conversations that support the future of psychedelic medicine.

Attending ICPR 2026? The team welcomes the opportunity to meet with shareholders, researchers, clinicians, industry participants, and potential partners throughout the conference.